Physician profile
Nicholas Spetko
NPI 1235121047
$2,212.56
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $631 · 2020: $613 · 2021: $433 · 2022: $34.00 · 2023: $106 · 2024: $394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $501.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $500.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $396.95 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $299.82 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $195.99 | 2021 | |
| Pfizer INC. | $163.52 | 2019-2024 | |
| Esperion Therapeutics, INC. | $138.35 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $133.57 | 2019-2024 | Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $126.35 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $92.93 | 2019-2021 | |
| Lilly USA, LLC | $91.44 | 2019-2021 | |
| Amarin Pharma, INC. | $74.10 | 2019-2020 | |
| Exact Sciences Corporation | $48.78 | 2024 | Cologuard Collection Kit |
| Abbvie INC. | $41.19 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $40.46 | 2019 | |
| Astellas Pharma US INC | $38.80 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.93 | 2023-2024 | Ofev |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $29.43 | 2019 | |
| Sanofi-Aventis U.S. LLC | $28.19 | 2019 | |
| Eisai INC. | $27.65 | 2020-2021 | |
| Hikma Pharmaceuticals USA | $27.18 | 2019 | |
| Jazz Pharmaceuticals INC. | $26.21 | 2024 | |
| Inspire Medical Systems, INC. | $24.15 | 2023 | Inspire |
| Hologic Sales and Service, LLC | $23.00 | 2023 | Aptima |
| Bayer Healthcare Pharmaceuticals INC. | $22.11 | 2024 | |
| Xeris Pharmaceuticals, INC. | $18.85 | 2024 | Gvoke Hypopen |
| Daiichi Sankyo INC. | $15.94 | 2020 | |
| Sanofi Pasteur INC. | $14.05 | 2019 | |
| Amgen INC. | $13.40 | 2021 | |
| Allergan, INC. | $12.47 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Spetko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.